S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIBJuan Miguel Bergua Burgués, Pau Montesinos, Marta Valero et al.|HemaSphere|2023Cited by 6
Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed <i>FLT3</i>-ITD Negative AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Blood|2024Cited by 5
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trialClaudia Sargas, Pau Montesinos, Augustin Boudry et al.|Blood|2025Cited by 3
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic RegistryDavid Martínez‐Cuadrón, Pau Montesinos, Blanca Boluda et al.|Blood|2023Cited by 2
Conventional PCR Versus Next Generation Sequencing for Diagnosis of <i>FLT3</i>, <i>IDH</i> and <i>NPM1</i> Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema GroupBlanca Boluda, Pau Montesinos, Claudia Sargas et al.|Blood|2022Cited by 1